Innovating Non-Invasive Delivery Routes for Next-Generation Exosome Therapeutics
Inhaled delivery offers unique advantages for exosome therapeutics, including:
- Targeted Pulmonary Delivery
Ideal for lung-related diseases such as asthma, COPD, ARDS, fibrosis, and viral respiratory infections.
Provides high local concentration with reduced systemic side effects.
- Non-Invasive and User-Friendly
Eliminates injectable routes, have the potential to improve patient compliance towards treatment, and supports at-home administration.
- Rapid Absorption & Systemic Reach
Nasal delivery enables fast uptake and the potential for nose-to-brain transport via the olfactory pathway.
- Maintained Exosome Integrity
Formulations are designed to preserve vesicle structure, bioactivity, and therapeutic performance throughout aerosol generation.
- Scalable & Stable Formats
Spray-dried and freeze-dried exosomes minimize cold-chain reliance and simplify global distribution.
Esco Aster offers advanced formulation solutions for inhalation-based exosome delivery, enabling developers to transform exosome candidates into nasal spray, nebulizer-ready, or dry powder inhalation products. By integrating specialized particle engineering, stability studies, and aerosolization expertise, we support the development of inhaled exosome therapeutics designed for respiratory, neurological, and systemic indications.
Esco Aster formulates exosomes for nasal delivery, optimizing for efficient mucosal absorption and stability.
Available formats include:
- Liquid formulations
- Freeze-dried powders for reconstitution
This route supports rapid systemic uptake and potential nose-to-brain delivery.
Exosomes can be engineered for compatibility with common jet and mesh nebulizers, ensuring structural integrity and consistent aerosol performance.
Capabilities include:
- Liquid formulations for immediate use
- Spray-dried or freeze-dried powders
Each formulation is optimized to withstand
aerosolization stress without compromising therapeutic potency.
For long-term stability and global distribution, Esco Aster offers advanced drying approaches:
- Spray-dried powders with controlled particle size distribution
- Freeze-dried powders with excellent reconstitution characteristics
- Formats suitable for DPIs or nebulizer reconstitution
These enable reduced cold-chain requirements and scalable manufacturing.
Format | Description | Use Case | Stability Profile |
|---|
Liquid
(Nasal) | Exosomes in buffered solution | Immediate-use nasal sprays | Refrigerated or frozen |
Freeze-Dried (Lyophilized) | Powder reconstituted upon use | Nebulizers, DPIs | Excellent long-term stability |
Spray-Dried | Dry powder with optimized particle size | Dry powder inhalers (DPIs) | High reconstitution yield, ambient stability |
Delivery Route | Onset of Action | Target Precision | Typical Use | Key Advantage |
|---|
| Nasal Spray | Rapid
| High (mucosal & possibly brain) | Olfactory, systemic therapy | Non-invasive, fast absorption |
| Nebulization (Liquid) | Moderate | Local (lungs) | Pulmonary diseases | High lung deposition, scalable dosing |
| Dry Powder Inhalation | Variable (depends on breathing) | Local (lungs) or systemic | Chronic respiratory conditions | No cold chain, portable |
- Targeted Pulmonary Delivery: Enables high local concentrations in the lungs for diseases such as asthma, COPD, ALI/ARDS, and pulmonary fibrosis. (Parkinson)
- Non-Invasive: Eliminates need for injections, enhancing patient comfort and adherence.
- Nose-to-Brain Delivery: Nasal delivery may leverage the olfactory route for neurological or CNS-targeted therapies.
- Rapid Systemic Uptake: In some cases, inhaled exosomes can enter the bloodstream more quickly than injected forms.
- Stability: Spray-dried and freeze-dried formulations designed for high stability with reduced cold-chain needs.
- Preserved Bioactivity: Formulations are engineered to maintain exosome integrity and functional capacity through drying and aerosolization.
- Respiratory diseases (e.g. asthma, COPD, ARDS)
- Infectious lung conditions
- Neurodegenerative or neurological disorders (via nose-to-brain)
- Systemic inflammatory diseases
- Regenerative and reparative medicine
- Parkinson's disease
With deep expertise in exosome characterization, formulation science, and scalable processing including drug product fill & finish.
Esco Aster provides an integrated platform to advance inhalable exosome therapeutics from concept to clinic. Our team ensures product stability, regulatory readiness, and manufacturing feasibility to accelerate innovation in non-invasive biologic delivery.
Contact Esco Aster to explore how our inhalation exosome formulation services can support your therapeutic development needs.
Esco Aster Drug Product Fill & Finish for Aseptic Processing of Advanced Therapeutics